Skip to main
  1. Stocks
  2. Diebold Nixdorf Inc
  3. Forecast
DBD

DBD Stock Forecast & Price Target

DBD Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Diebold Nixdorf is positioned for fundamental improvement because leadership-backed estimates already appear derisked through next year, while upside remains from Services gross margin expansion, lower operating expense, and better price capture. The company’s Banking franchise is still steady, and its fast-growing North America Retail business, including Smart Vision AI and self-checkout wins, is driving double-digit POS growth and helping offset tougher ePOS comparisons. Financially, 2026 adjusted EBITDA is estimated at $495M versus $520M in 2027, FCF is expected to rise from about $150M to $225M, and net leverage below 1.5x supports buybacks and strategic flexibility.

Bears say

Diebold Nixdorf is facing a weak fundamental setup because its banking and retail businesses are exposed to lumpy upgrade cycles, falling ATM demand, and intensifying competition from digital and alternative payment methods. Despite CQ3 revenue of $991M, adjusted EBITDA of $128M, and adjusted EPS of $1.34 beating estimates, management cut 2026 guidance to $3.86B-$3.90B revenue, $490M-$510M EBITDA, and $190M-$210M FCF as mix shifts, memory inflation, and delayed banking deals pressure margins and cash generation. The deterioration in non-GAAP corporate gross margin to 25.3%, retail gross margin to 20.7%, and the loss of targeted service margin expansion suggest pricing power remains limited and the earnings recovery is being pushed further out.

DBD has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Diebold Nixdorf Inc and is not a guaranteed prediction by Public.com or investment advice.

DBD Analyst Forecast & Price Prediction

Get the latest DBD stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in DBD

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Diebold Nixdorf Inc (DBD) Forecast

Analysts have given DBD a Buy based on their latest research and market trends.

According to 2 analysts, DBD has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $85, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $85, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Diebold Nixdorf Inc (DBD)


DBD Analyst Forecast & Price Prediction

Get the latest DBD stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in DBD

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover DBD stock data and trends